Categories
Uncategorized

News to Concentrate: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), settled the day at a share price of $18.81 after seeing a rise of 1.29% that brought its market cap to $975.11 million. When looking at performance, we see the stock demonstrating a weekly performance of 10.06% while keeping a monthly performance of 16.47%. Quarterly performance saw a drop of -20.45% and continued the negative trend with a yearly performance of -51.28% while showing YTD performance of -20.7% which was -26.92% for last six months. The 52-week range for the stock was 13.12 – 39.10 that put its current price at a premium of 43.37% to the 52-week low price whereas it is trading at a discount of -51.89% to the 52-week high price.

On January 21, 2020, Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), announced that the U.S. Food and Drug Administration (FDA) has found the New Drug Application (NDA) for SPN-812 for the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD) acceptable for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 8, 2020.  “SPN-812, if approved by the FDA, will be the first truly new therapy to treat ADHD in a decade,” said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “This is critical for the nearly 6.1 million children and adolescents in the U.S. who are diagnosed with the condition and are in need of a treatment that is a non-controlled substance and that works differently from currently available treatments.”

The NDA for SPN-812 is based on data from an extensive development program consisting of four Phase III clinical trials that studied the pediatric patient population from the age of 6 to 17 years, two Phase II clinical trials, several Phase I trials, a long-term open label extension study, preclinical testing, and drug manufacturing data.  Each of the four pivotal clinical trials showed a reduction in ADHD-RS-5 total score as early as Week 1 and continuing until the end of the clinical study, as well as improvement in both hyperactivity/impulsivity and inattention subscales.  The effect was statistically significant for the studies for 100mg, 200mg, and 400mg doses.  SPN-812 had an acceptable safety profile with low incidence of adverse events and low discontinuation rates. In addition, during the fourth quarter of 2019, the Company initiated a Phase III program to study SPN-812 in the adult ADHD patient population.

The Generic Drugs company is currently upholding a gross margin of 95.8% while maintaining a net profit margin of 28.8%. Operating margin for the last 12 months remained 37.8%. The company’s EPS for trailing 12 months is $2.11 and it is estimated to be posting an EPS of $0.27 for the current quarter. The Beta number showed the stock is subject to risk 50% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is 10.4% while ROE for the same period is 21% and have seen an average of 12.1% return on investment (ROI). The outstanding share count is 51.84 million shares but the size of available float is 50.74 million shares.

The stock’s current price is lagging SMA-200 by -24.58% which is also -3.89% down from SMA-50. Reducing that period to a shorter term, we see the price is trailing 12.94% to the SMA-20. Volatility for the week was 5.42%, which was 9.09% in the previous month. The company closed the session with a trading volume of 491.56 thousand shares, below from its average daily trading volume of 630.38 thousand. It has been generating revenue of $392.8 million while net income posted by the company in last 12 months was $113.1 million.

Categories
Uncategorized

Stock News & Research: MKS Instruments, Inc. (NASDAQ:MKSI)

MKS Instruments, Inc. (NASDAQ:MKSI), concluded the day at $86.52 after seeing a fall of -3.72% that brought its market cap to $4.93 billion. The 52-week range for the stock was 66.87 – 122.30 that put its current price at a premium of 29.39% to the 52-week low price whereas it is trading at a discount of -29.26% to the 52-week high price. The Scientific & Technical Instruments company is currently upholding a gross margin of 43.7% while maintaining a net profit margin of 7.4%. Operating margin for the last 12 months remained 11.6%.

On April 08, 2020, MKS Instruments, Inc. (NASDAQ: MKSI), announced that due to the public health impact of the novel coronavirus (COVID-19) and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its shareholders and company personnel, it will change the date of its annual meeting of shareholders to Monday, May 11, 2020 and will hold this meeting via remote communication only. Shareholders will be able to participate in the annual meeting of shareholders only via the virtual meeting. As previously announced, the meeting will be held at 10:00 a.m. Eastern Time.

As described in the proxy materials for the annual meeting of shareholders previously distributed, shareholders are entitled to participate in and vote at the annual meeting of shareholders if they were a shareholder as of March 4, 2020, the record date, or hold a legal proxy for the meeting provided by the shareholder’s bank, broker or nominee as of such record date. Shareholders may submit questions during the live virtual meeting through the virtual meeting platform.  Those who do not have a control number may attend as guests of the meeting but will not be able to vote shares or submit questions during the virtual meeting.  The meeting will employ online tools that ensure shareholders have the same rights and opportunities to participate as they would at an in-person meeting.

The company’s EPS for trailing 12 months is $2.54 and its annual dividend yield is 0.92% with a payout ratio of 31.2%. It is estimated to be posting an EPS of $1.26 for the current quarter. The Beta number showed the stock is subject to risk 47% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is 4.1% while ROE for the same period is 7.1% and have seen an average of 6.3% return on investment (ROI). The outstanding share count is 56.94 million shares but the size of available float is 54.23 million shares. The stock’s current price is lagging SMA-200 by -9.56% which is also -10.3% down from SMA-50. Reducing that period to a shorter term, we see the price is trailing 7.74% to the SMA-20. Volatility for the week was 7.11%, which was 0.70% in the previous month.

The company closed the session with a trading volume of 492.28 thousand shares, above from its average daily trading volume of 491.17 million. It has been generating revenue of $1.9 billion while net income posted by the company in last 12 months was $140.4 million. When looking at performance, we see the stock demonstrating a weekly performance of 11.21% while keeping a monthly performance of -3.53%. Quarterly performance saw a drop of -21.42% and continued the negative trend with a yearly performance of -11.31% while showing YTD performance of -21.35% which was -3.3% for last six months.

Categories
Uncategorized

News that’s moving Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA), ended the day at $12.62, a rise of 1.2 per cent and a share price that brought its market capitalization to $625.12 million. The company’s EPS for trailing 12 months is $-2.11 and its annual dividend yield is 0% with a payout ratio of 0%. It is estimated to be posting an EPS of $-0.45 for the current quarter. The Beta number showed the stock is subject to risk 76% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is -28.9% while ROE for the same period is -36.6%.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) that works focusing around developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application submitted by its collaborator, Novartis, for a CRISPR/Cas9-based engineered cell therapy for the treatment of sickle cell disease (SCD).

In the 1/2 phase of this clinical trial, the leading genome editing company will begin investigating OTQ923 in adult patients with severe complications of SCD. OTQ923 is a SCD treatment based on genome editing of hematopoietic stem cells (HSCs), using CRISPR/Cas9 RNA guides identified through Intellia’s cell therapy research collaboration with Novartis. This therapeutic approach results in highly targeted editing of the HSC’s DNA to induce fetal hemoglobin (HbF) expression. The edited cells are returned to the patient, where the expression of HbF is expected to reduce the deleterious effects of sickle hemoglobin (HbS). Novartis’ IND application triggered a milestone payment to Intellia, and the company is eligible to receive additional downstream success-based milestones and royalties.

The outstanding share count is 50.13 million shares but the size of available float is 40.74 million shares. The stock’s current price is lagging SMA-200 by -12.35% which is also -2.44% down from SMA-50. Reducing that period to a shorter term, we see the price is trailing 5.84% to the SMA-20. Volatility for the week was 6.81%, which was 1.03% in the previous month. The company closed the session with a trading volume of 498752 shares, below from its average daily trading volume of 760.2 million.

It has been generating revenue of $43.1 million while net income posted by the company in last 12 months was -$99.50 million. When looking at performance, we see the stock demonstrating a weekly performance of 11.94% while keeping a monthly performance of -9.44%. Quarterly performance saw a drop of -18.01% and continued the negative trend with a yearly performance of -27.71% while showing YTD performance of -15% which was 15.36% for last six months.

The 52-week range for the stock was 9.18 – 19.00 that put its current price at a premium of 37.47% to the 52-week low price whereas it is trading at a discount of -33.58% to the 52-week high price.